23 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
, with the most common TEAEs being COVID-19, cough, dyspnea, and wheezing. Of note, this trial was started during the worldwide COVID-19 pandemic and COVID
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
was started during the
worldwide COVID-19 pandemic and COVID-19 adverse events were noted across all treatment groups. No new safety signals were
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, pandemic, fire, earthquake, flood, storm or like catastrophe
6-K
EX-99.1
1cro6lupsab zl7je
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
42wd1qe 4a
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
20-F
3pjv14tuqngbk8d6nkao
31 Mar 22
Annual report (foreign)
4:33pm
6-K
t4g y2uzrm5bbk
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.2
sdwbioxg
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.1
j7xn464s9
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.1
ac368mxea
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
EX-99.3
pv4wzk0iq935b0l
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.1
u5l9d
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.2
l4mi l90b02g6vdm
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
424B4
rpsic5
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1/A
wq5ypt9 tdd
18 Mar 21
Registration statement (foreign) (amended)
6:15am
F-1/A
2kd4yhzlnc3q
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
CORRESP
p3wiypfckydu
8 Mar 21
Correspondence with SEC
12:00am
F-1
EX-10.14
rug2kah80klikl1b9k
26 Feb 21
Registration statement (foreign)
4:56pm